Leuplin leuprorelin acetate regulatory update

Takeda submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for a 6-month formulation of Leuplin leuprorelin acetate to treat prostate cancer and premenopausal breast cancer. Leupl...